The role of nucleoside analogues (NAs) in lipodystrophy (LD) syndrome in human immunodeficiency virus (HIV)-infected patients remains controversial. We studied the prevalence of LD in previously untreated patients randomized to receive different NA combinations (in the ALBI-ANRS 070 trial) for 6 months. At month 30 of follow-up, 37 (31%) of 120 patients had у1 morphologic change, and 21 (57%) of 37 had isolated peripheral lipoatrophy; corresponding values for the patients who received only NAs throughout follow-up were 20 (30%) of 66 and 14 (67%) of 21, respectively. In multivariate analysis, factors associated with presence of LD at month 30 were initial assignment to the group receiving stavudine and didanosine (odds ratio [OR], 6.7; ), age P p .02
changes [3] . These complications are relatively frequent among antiretroviral-treated patients, especially in patients who receive treatment with protease inhibitors (PIs) [4] , and there is no formal report on morphologic changes in antiretroviral-naive patients. Therefore, it has been suggested that there is a relationship between exposure to PIs and the occurrence of LD (i.e., morphologic changes) or lipid/glucose disorders (i.e., metabolic changes).
More recently, among patients who received only nucleoside analogues (NAs), treatment with lamivudine (3TC) [5] and stavudine (d4T) [6] has also been associated with the occurrence of these disorders. A better understanding of the respective role of these drugs in the onset of LD is important, because the attribution of LD to any specific drug(s) would have implications for clinical care as well as for an improved understand-ing of the pathogenesis of the LD syndrome. We undertook a study of patients in the long-term follow-up phase of a randomized clinical trial (which had initially aimed to compare different NA regimens) to explore which factors were associated with LD syndrome, with a particular emphasis on the antiretroviral regimens involved.
MATERIALS AND METHODS

Design and setting.
The results of the Alternance de Bitherapies-Agence Nationale de Recherche sur le SIDA, Essai 070 (ALBI-ANRS 70) trial have already been reported elsewhere [7] . In brief, 151 previously untreated HIV-infected patients with CD4
ϩ cell counts у200 cells/mL and plasma HIV-1 RNA levels of 10,000-100,000 copies/mL were randomly assigned to receive 6 months of open-label treatment in 1996-1997 with 1 of the following 3 regimens: (1) zidovudine (Zdv) plus 3TC (Zdv-3TC), or (2) d4T plus didanosine (ddI) followed by Zdv-3TC (alternating), or (3) d4T plus ddI (d4T-ddI). This trial showed that d4T-ddI was more effective than other combinations in reducing plasma HIV-1 RNA and increasing CD4 ϩ cell counts. At the end of the trial (6 months after randomization), patients were asked to participate in the long-term follow-up of this trial for an additional 24 months, with 1 visit every 3 months. All patients gave written informed consent for this long-term follow-up, and the clinical research was conducted in accordance with guidelines for human experimentation as specified by French law. Any changes in antiretroviral therapy made after the first 6 months of this study were made at the discretion of the physicians administering the treatments. Investigators were asked to collect follow-up data, including medication history, prospectively on a standardized questionnaire. At the last follow-up visit, 30 months after the initiation of antiretroviral treatment, body weight, CD4 ϩ cell count, plasma HIV RNA measurements, and morphologic and metabolic data were recorded. Physicians were also specifically asked to report any sign of LD and to classify patients as having one of the following clinical signs: (1) isolated peripheral lipoatrophy (fat loss from face, arms, buttocks, and legs, and prominent superficial veins), (2) isolated central fat accumulation (increased waist size, "buffalo neck," increased cervical size, or breast enlargement), or (3) mixed syndrome (associated lipoatrophy and central fat accumulation). The investigator was not blinded to the treatments received by the patients. Furthermore, each clinical sign of LD was graded by the physician as mild (noticeable only when specifically sought), moderate (obvious to the patient or the physician), or severe (obvious to any casual observer). We considered that LD syndrome was present when at least 1 of the 3 specified clinical signs was present. In addition, glucose/lipid metabolism was evaluated by measuring levels of fasting blood glucose, triglycerides, total cholesterol, and In order to study the relationships between individual drugs and LD, we used different explanatory variables: either (1) a variable that reflected classes of antiviral therapy received through month 30; NAs only, NAs and a PI, or NAs and nonnucleoside reverse-transcriptase inhibitors (NNRTIs); or (2) a variable that reflected the NAs received through month 30: either the regimen initially assigned (d4T-ddI, Zdv-3TC, or alternating) or the pattern of exposure to NAs throughout follow-up (Zdv-3TC only, Zdv-3TC followed by d4T-ddI, d4T-ddI followed by Zdv-3TC, or d4T-ddI only). Patients who received d4T plus 3TC ( ) were classified in either the n p 15 second or the third group, according to the combination they received initially.
These estimations were adjusted for all available covariates potentially associated with the presence of LD: (1) ternating arm participated, and 37 (73%) of 51 from the d4T-ddI arm participated ( ). P p .18 At month 30, the mean decreases in the plasma HIV RNA level from baseline was 0.52 log 10 copies/mL in the Zdv-3TC group, 0.64 log 10 copies/mL in the alternating group, and 0.65 log 10 copies/mL ( ) in the d4T-ddI group. The corre-P p .71 sponding mean increases in the CD4 ϩ cell count were 144, 161, and 188 cells/mm 3 , respectively ( ). P p .74 Treatment received. During the first 6 months after randomization (i.e., the randomized part of the observation), no PI or NNRTI was administered in combination with the initial NA combination. During months 6-30, 66 patients received only NAs, 33 switched to a PI-containing regimen, and 21 switched to a NNRTI-containing regimen. In the Zdv-3TC group, 15 patients (38%) continued to receive NAs alone throughout follow-up; in the alternating group, 25 patients (58%) received NAs alone, and in the d4T-ddI group, 26 patients (70%) received NAs alone ( ). P p .07 When patterns of exposure to NAs throughout follow-up are considered and combinations with PIs or NNRTIs are ignored, 17 patients (14%) received only Zdv-3TC. For 23 patients (19%), Zdv-3TC therapy was followed at some point by d4T-ddI therapy, and, for 54 patients (45%), d4T-ddI therapy was followed by Zdv-3TC therapy. Finally, 26 patients (22%) received only d4T-ddI. The median duration of exposure to Zdv-3TC for these 4 groups was 28.5, 13, 10.6, and 0 months, respectively. The median duration of exposure to d4T and ddI for these 4 groups was 0, 11.3, 8.5, and 29 months, respectively.
Prevalence of LD at month 30. Overall, LD was reported in 37 patients (31%; 95% CI, 23%-40%), isolated peripheral lipoatrophy was reported in 21 patients (18%; 95% CI, 11%-26%), isolated central fat accumulation was reported in 7 patients (6%; 95% CI, 2%-12%), and mixed syndrome was reported in 9 patients (7%; 95% CI, 4%-14%; table 1). In the 66 patients who only received NAs throughout follow-up, the overall frequency of LD was 30% (peripheral lipoatrophy, 21%; central fat accumulation, 3%; and mixed syndrome, 6%). These proportions were not statistically different from those among patients who received a PI or NNRTI in addition to NAs at some point during follow-up. (For the sake of simplicity, cases of isolated central fat accumulation were pooled with cases of mixed syndrome.) The same trends were observed when only moderate and severe signs were considered, although those were less frequent by far.
When metabolic parameters measured at month 30 were considered, the proportion of patients with abnormal lipid levels was high in all 3 groups: 25% had a fasting triglyceride level of at least 2.2 mM, and 40% had a fasting cholesterol level of at least 5.5 mM. No difference was observed for plasma glucose and cholesterol levels at month 30 among the groups receiving different classes of drugs. However, the mean triglyceride level was always lower in the group that received NAs only.
Factors associated with LD syndrome. In the univariate analysis of clinical manifestations of LD syndrome (table 2) , mean age was significantly greater among patients who presented with LD than among patients who did not. There was no difference in virologic response at month 6 (i.e., the time at which the drugs regimens could be switched) as a function of the presence of LD. Nonetheless, the virologic response at month 30 was better in patients with LD than in patients without LD. When we considered combinations of NAs throughout follow-up, we found that starting with a d4T-ddI regimen was associated with a higher prevalence of LD at month 30 than were other patterns of drug therapy. No significant differences were found with respect to sex, baseline CD4 ϩ cell count, CD4
ϩ cell response at month 6 or month 30, and exposure to a PI or NNRTI during months 6-30 of follow-up. The trends were similar among patients who received NAs only. When the initial randomization group was included in the multivariate analysis of factors associated with the clinical manifestations of LD syndrome (table 3) , initial assignment to the d4T-ddI group was still associated with the presence of LD at month 30 (adjusted OR, 6.7, vs. Zdv-3TC; ), whereas P p .02 assignment to the alternating group was not (adjusted OR, 3.2, vs. Zdv-3TC;
). The same trends were observed when P p .14 only moderate and severe LD or peripheral lipoatrophy were considered as dependent variables.
When patterns of exposure were included in the multivariate analysis of clinical manifestations of LD syndrome (table 4) , the consecutive association of Zdv-3TC therapy followed by d4T-ddI therapy was not significantly associated with the presence of LD at month 30 (adjusted OR, 6.2, vs. Zdv-3TC therapy only;
). However, the consecutive association of d4T-P p .12 ddI therapy with Zdv-3TC therapy was significantly associated with the presence of LD at month 30 (adjusted OR, 8.7, vs. Zdv-3TC therapy alone; ), as was receiving only d4T-P p .04 ddI (adjusted OR, 26.41, vs. Zdv-3TC therapy alone; P p ). .006
Finally, we did not find any association between exposure to NAs (whatever the categorization) and any metabolic disorder (hypercholesterolemia, hypertriglyceridemia, or hyperglycemia; data not shown). Elevated triglyceride levels were more frequently observed among patients who received a PI and those with a BMI у25 kg/m 2 , and elevated cholesterolemia was more common among older patients.
DISCUSSION
In a study in which antiretroviral-naive patients were initially randomized to receive different NA combinations, we have shown that LD syndrome, especially peripheral lipoatrophy, was frequent among patients with 30 months of exposure to NAs with or without PIs or NNRTIs. Morphologic changes were of mild severity in 140% of patients. A higher age at baseline, a lower BMI at baseline, a better virologic response at month 30, and initial randomization to receive d4T-ddI were associated with development of this syndrome. Overall, the fasting triglyceride level was 12.2 mM in 25% of patients, and the total cholesterol level was 15.5 mM in 40% of patients; rates of abnormal glucose/lipid levels showed no difference that corresponded to exposure to Zdv-3TC or d4T-ddI.
For patients who receive a PI, numerous studies have reported a highly variable prevalence of LD syndrome, although it tends to be 160% in larger studies [3, 8, 9] . However, large studies that have dealt with the prevalence and determinants of the LD syndrome in patients who receive only NAs are sparse. Sutinen and Mathur-Wagh [10] reported that 13 (41%) of 32 women receiving such therapy had an increased abdominal girth. In a study by Carr et al. [11] , lipodystrophy was diagnosed in 1 (3%) of 32 PI-naive patients after a mean follow-up of 14 months. To date, the 2 largest published studies that have included antiretroviral-treated PI-naive patients are the Aquitaine Cohort study, which reported a prevalence of 25% of LD syndrome among 179 patients [12] , and the Western Australian HIV Cohort Study, which observed fat wasting of 13% in 71 patients [13] . In both studies, investigators reported the development of morphologic abnormalities a long time after the initiation of NAs, compared with reports for patients who received a PI. A possible explanation for this difference could be that caregivers are more sensitive to the occurrence of this syndrome in patients receiving a PI and ignore more-subtle body-shape changes in patients not treated with a PI. Alternatively, it may be that PIs amplify already preexisting metabolic disorders in NA-treated patients [13] . Many factors have been reported to contribute to the variability of the prevalence of morphologic or metabolic changes. These include sex, age, weight change, BMI, waist-to-hip ratio, duration of antiretroviral therapy, duration of treatment with a highly active antiretroviral regimen, and prior treatment reg- imens [2, 5, 6, 8, 9, [11] [12] [13] [14] [15] [16] [17] . Behaviors, such as diet or exercise, may also affect the development of the syndrome [18] . In our study, the proportion of women was too low to allow any comparison between sexes. As in other reports [1, 11] , we confirmed that the group of patients with the best virologic responses to antiviral therapy had a higher frequency of morphologic or metabolic abnormalities. In our study, patients with a higher BMI had a lower risk of developing LD. This result was unexpected, although it could be explained by the fact that lipoatrophy was the clinical manifestation most frequently reported. LD syndrome is frequently associated with metabolic changes. In our study, glucose levels and lipid metabolism were moderately affected at the end of month 30 of follow-up; moresignificant changes have been seen in patients receiving PI therapy [19] [20] [21] . In untreated HIV-infected patients, serum triglyceride levels may well be abnormally high [22] , which is associated with disease progression and immune dysregulation [23] . In one cohort of patients who were considered to have a stable response to antiretroviral therapy, higher triglyceride levels were more frequently encountered in patients who had a higher BMI or who were switched to a PI [12] . Conversely, no difference was observed in cholesterol or glucose levels in the NA-only subgroup, compared with levels in the PI and the NNRTI groups.
Our study was cross-sectional, and we report our findings as the prevalence of LD. However, because the frequency of LD has been reported to range from 0% [24] to 5% [25] in subgroups of antiretroviral-naive patients, we assume that all cases of LD diagnosed at the end of follow-up in our study occurred after exposure to antiretroviral treatment, and the reported frequency, therefore, may be considered to be a cumulative incidence at month 30, rather than a prevalence. Because the exact date of onset of LD could not be ascertained, it is therefore difficult to make formal conclusions about the causal role of factors found to be associated with a higher frequency of morphologic changes. Moreover, the reported ORs have to be interpreted as values for exposure to d4T-ddI versus Zdv-3TC, rather than as values for exposure to d4T alone or exposure to 3TC alone versus another NA alone. Nevertheless, we limited confusion biases in the comparisons between the different treatment patterns by adjusting for potential determinants of LD as much as possible [26] .
In our study, physicians were not blinded to the treatment that patients received. This could have resulted in an overestimation of the already high frequency of morphologic changes observed, especially those changes associated with d4T, given that early studies of the association between d4T and lipoatrophy [6] were published at the same time that the 30-month visits took place, in 1999. Moreover, a subjective clinical definition of LD was used by the physicians administering the treatments, and 43% of the cases were rated as being of mild severity only. This lack of objectivity must be overcome by a standardized definition of LD, and all efforts to agree on such a definition should be supported [27] . Nevertheless, we believe that the association between LD and d4T-ddI therapy in our study was so strong that it cannot be ruled out.
Different hypotheses have been offered about the pathogenesis of this syndrome. Some authors have suggested that PIs are its main cause [28] [29] [30] . However, this does not explain why LD syndrome is also reported in patients who have never received a PI. NAs can inhibit DNA polymerases other than HIV reverse transcriptase, including mitochondrial DNA polymerase g. Because lipolysis is an energy-dependent process, it has been suggested that LD is a manifestation of mitochondrial damage attributable to NA therapy [31, 32] , as it might be for other toxicities [33, 34] . However, only the relationship of Zdv with myopathy is clearly proven. Recently, 3 observational studies have reported a specific association between exposure to d4T and peripheral lipoatrophy [13, 14, 35] . These results are consistent with those of our study, in which lipoatrophy was the most frequent manifestation, especially in patients exposed to d4T-ddI. The side effects of d4T-ddI must then be balanced against their obvious antiviral efficacy [7] , particularly as we enter an era in which HIV infection is considered to be a chronic disease. LD syndrome, especially peripheral lipoatrophy, is frequent among patients with a long history of exposure to NAs. Age, BMI, virologic response, and exposure to d4T-ddI are important determinants of the frequency of this syndrome among such patients. There is an urgent need for a consensus case definition of LD as well as for prospective studies that could permit a thorough description of the natural history of the LD syndrome. Randomized, controlled trials of new treatment strategies should include body composition and metabolic studies that use blinded assessments to directly test hypotheses about drug causality [4] and should evaluate the ratio of benefit to risk for specific treatment combinations. Prolonged followup will allow for description of the long-term consequences of these morphologic and metabolic changes, such as cardiovascular risk.
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